Month: September 2013

RMTI, PHOT & Extended Watchlist

Rockwell Medical, Inc. RMTI

We mentioned RMTI in Friday’s extended watchlist, and it turned out to be a good decision on our part. After opening at a low of 8.75, the price surged ahead to touch 10.20, marking an opportunity at intraday gains of up to 17%

We’re going to leave RMTI on our radars as we kick off a fresh week of trading, as the stock appears to be gapping up this morning, (presently above Friday’s high, trading at 10.50 premarket). The stock also traded high volume on Friday, so we want to monitor the situation for any further gains the current flux of momentum might provide.

Growlife, Inc. PHOT

PHOT had a good day on Friday as well, breaking a recent double-top, posting gains on increased volume. The stock hit a high .0477, which from the low following our most recent mention of this play (.0318), represents a 50% move.

We’ve got this and other marijuana-related stocks on continuous watch since the USDOJ announcement that the federal government would not be interfering with individual states that have voted to legalize the plant for both medical and personal use.

Extended Watchlist:
EXMT, IGLD, INO, BZ, ZQK, GOGO

FREE, VCLK & Extended Watchlist

FreeSeas, Inc. FREE

We mentioned FREE on Tuesday after it set off our irregular volume scanner. We’re still watching this stock, as it has managed to achieve higher lows and higher highs every day since then while maintaining much of that volume and momentum. We generally consider a setup like this to be a bullish signal, so we’ll be monitoring the situation as we close out the week. So far, from Tuesday’s low (.2213) to yesterday’s high (.3346), our total possible gain on this play in just three sessions amounts to 51%

We mentioned that our main areas of resistance here were at .33 and .38, and that statement still holds true.

VCLK Options
We were looking at the 09/21 $21 Calls on VCLK a couple of weeks back, so let’s look at what they’ve done for us in the meantime. At the time they were trading in the .60-.80 range, and have since hit a high 1.45, reached at yesterday’s close. We are going to want to keep an eye on these calls heading into their expiration at the end of next week. Provided VCLK continues to fill its recent gap-down (pointed out in our previous report) and push us further into the money, we should continue to see gains from these contracts.

Extended Watchlist:
OCLR, CTIC, ONCY, SGMO, RMTI, CUR

AXXE | Axxess Pharma, Inc. | Today’s Focus


Axxess Pharma, Inc. AXXE

We’re putting AXXE on our radars this morning, a new play with a chart that appears to have potential. As always when we focus on a new company, we’d first like to take a few minutes to familiarize ourselves with the business behind the stock.

Axxess Pharma has an expansive line which includes twenty-three prescription and non-prescription strength products, which are used in the treatment of a variety of ailments, including but not limited to: iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, and joint pain.

The company has been taking steps to make these products available to the public at an affordable price.

AXXE recently signed an agreement with a Mexican pharma company that will facilitate the distribution of its Soropon product to the Mexican population, which, according to President and CEO Dr. Daniel Bagi, is ” three times that of Canada’s and has a higher birth rate than Canada. AXXE is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014.”

That and more was covered yesterday when we conducted an Exclusive Interview with Dr. Bagi via our sister site, Stock Traders Talk. It covered a lot of important things, so be sure to take a few minutes to check that out on StockTradersTalk.com when it becomes available this afternoon!

AXXE EXCLUSIVE INTERVIEW
Available after 1:00PM today, only on Stock Traders Talk!

Now to go over the AXXE chart, for which we’ve provided the following video presentation:

Axxess has been awfully busy of late, making several news announcements already this month. Between its active approach to shareholder outreach via press release, as well as the CEO making the time to take part in our interview, we can see that this company places a high emphasis on transparency and visibility. To that end, if you read ahead to the PRs, we find that AXXE is actually making preparations for an uplisting to the OTC Bulletin Board.

SEPTEMBER PRESS RELEASES:

09.11.13: Axxess Pharma Inc. Initiates Next Step Towards Bulletin Board (OTCBB) Listing

09.09.13: AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical Company

09.04.13: Axxess Pharma Inc. Announces US Board Certified Cardiologist, Dr. Fred Maese as Senior Consultant

09.02.13: Axxess Pharma Inc. Announces MOU to Acquire Leading Canadian OTC Healthcare Company

More Info is available at:
www.axxesspharmainc.com